Tag Archive for: gene therapy

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy

/in

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median survival When used in combination with immune checkpoint blockade (ICB), AT-108 demonstrated strong anti-tumor activity, including significantly extending survival and achieving […]

Read more

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

/in

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a personalized anti-tumor immune response to benefit cancer patients in need   Lund, Sweden, 17 April 2026 – Asgard Therapeutics, a privately held biotech company pioneering […]

Read more

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

/in

Results presented today at ESGCT 2025 PARIS, France, LUND, Sweden (October 10, 2025) – Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV […]

Read more

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

/in

– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]

Read more

SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024

/in

BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce that its management team will be attending and presenting at key scientific and investor conferences in April to June 2024. Read more…

Read more